We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Hogan Lovells Advises on £135m Clinigen IPO

25 September 2012

LONDON, 25 September 2012 - Hogan Lovells has advised Numis Securities Limited in relation to the £135 million initial public offering (IPO) of pharmaceutical company Clinigen, admitted to AIM today, Tuesday 25 September. The float marks the first IPO of a UK pharmaceutical company since July 2007.

The placing raised £50 million from institutional investors, including £10 million of new money which Clinigen, a supplier of drugs for medical trials, will use to acquire drugs that it can sell in new markets or adapt for alternative uses.

Numis is acting as nominated adviser and broker to Clinigen, and also acted as sole book-runner on the IPO. The Hogan Lovells team which worked alongside General Counsel Michael Lee at Numis was led by London corporate partner Guy Potel, supported by Of Counsel Karla Dudek and associate Joanna Roberts, with U.S. advice provided by U.S. securities partner Peter Kohl.

Hogan Lovells secured the role through Co-Head of private equity Alan Greenough's relationship with broker Numis; having recently acted alongside them to advise AIM listed Abcam plc on its acquisition of the entire issued share capital of Epitomics International Inc for US$ 170 million in March 2012.

Commenting on the listing of Clinigen, Guy Potel said:

"In what are challenging times for equity capital markets, we were delighted to work with Numis in successfully bringing Clinigen to the market, marking the first IPO of a UK pharmaceutical company for five years."

 
Loading data